These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26185181)

  • 1. Understanding congestion in China's medical market: an incentive structure perspective.
    Sun Z; Wang S; Barnes SR
    Health Policy Plan; 2016 Apr; 31(3):390-403. PubMed ID: 26185181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of China's healthcare price reforms on traditional Chinese medicine public hospitals in Beijing: an interrupted time-series study.
    Zhu D; Shi X; Nicholas S; Bai Q; He P
    BMJ Open; 2019 Aug; 9(8):e029646. PubMed ID: 31401602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From a national, centrally planned health system to a system based on the market: lessons from China.
    Ma J; Lu M; Quan H
    Health Aff (Millwood); 2008; 27(4):937-48. PubMed ID: 18607026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot project using evidence-based clinical pathways and payment reform in China's rural hospitals shows early success.
    Cheng TM
    Health Aff (Millwood); 2013 May; 32(5):963-73. PubMed ID: 23552049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How China's new health reform influences village doctors' income structure: evidence from a qualitative study in six counties in China.
    Zhang S; Zhang W; Zhou H; Xu H; Qu Z; Guo M; Wang F; Zhong Y; Gu L; Liang X; Sa Z; Wang X; Tian D
    Hum Resour Health; 2015 May; 13():26. PubMed ID: 25940189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Realignment of incentives for health-care providers in China.
    Yip WC; Hsiao W; Meng Q; Chen W; Sun X
    Lancet; 2010 Mar; 375(9720):1120-30. PubMed ID: 20346818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Descending Resources Reform Improve Patient Satisfaction and Reshape Choice of Care Providers? A Cross-Sectional Study in Zhejiang, China.
    Sun Z; Wang S; Zhao H; Yu H
    Inquiry; 2020; 57():46958020956899. PubMed ID: 32909479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient dissatisfaction in China: What matters.
    Pan J; Liu D; Ali S
    Soc Sci Med; 2015 Oct; 143():145-53. PubMed ID: 26356826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the new maternity insurance scheme on medical expenditures for caesarean delivery in Wuxi, China: a retrospective pre/post-reform case study.
    Chen C; Cheng Z; Jiang P; Sun M; Zhang Q; Lv J
    Front Med; 2016 Dec; 10(4):473-480. PubMed ID: 27896623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Chinese healthcare system: structure, problems and challenges.
    Hougaard JL; Osterdal LP; Yu Y
    Appl Health Econ Health Policy; 2011; 9(1):1-13. PubMed ID: 21174479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. China's health system and its reform: a review of recent studies.
    Wagstaff A; Yip W; Lindelow M; Hsiao WC
    Health Econ; 2009 Jul; 18 Suppl 2():S7-23. PubMed ID: 19551753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serve the people or close the sale? Profit-driven overuse of injections and infusions in China's market-based healthcare system.
    Reynolds L; McKee M
    Int J Health Plann Manage; 2011; 26(4):449-70. PubMed ID: 22213261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risks and control of complete market-oriented reforms of medical institutions].
    Ding J; Tian Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Apr; 39(4):423-7. PubMed ID: 24820269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving towards a better path? A mixed-method examination of China's reforms to remedy medical corruption from pharmaceutical firms.
    Shi J; Liu R; Jiang H; Wang C; Xiao Y; Liu N; Wang Z; Shi L
    BMJ Open; 2018 Feb; 8(2):e018513. PubMed ID: 29439069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intended and unintended impacts of price changes for drugs and medical services: Evidence from China.
    Fu H; Li L; Yip W
    Soc Sci Med; 2018 Aug; 211():114-122. PubMed ID: 29935401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical device market in China.
    Boyer P; Morshed BI; Mussivand T
    Artif Organs; 2015 Jun; 39(6):520-5. PubMed ID: 25735659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary health care in China: is China's health reform reform for the whole nation?
    Cheng JM; Yuan YX; Lu W; Yang L
    Prim Health Care Res Dev; 2017 Jul; 18(4):398-403. PubMed ID: 28290254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do Chinese people perceive their healthcare system? Trends and determinants of public satisfaction and perceived fairness, 2006-2019.
    Zhu Y; Li Y; Wu M; Fu H
    BMC Health Serv Res; 2022 Jan; 22(1):22. PubMed ID: 34983522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing medical ethics in China's reform era.
    Ip PK
    Dev World Bioeth; 2005 May; 5(2):176-87. PubMed ID: 15842726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.